Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate vs methotrexate + leflunomide in psoriatic arthritis
NL-OMON21424Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in psoriatic arthritis (PsA) comparing Methotrexate monotherapy with Methotrexate + leflunomide (2 arms). Primary endpoint: Psoriatic Arthritis Disease Activity Score (PASDAS) at 16 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
methotrexateleflunomide
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON21424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21424.